Loading market dashboard
MoonLake Immunotherapeutics
MLTXHealthcareNASDAQCH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regarding its sonelokimab (SLK) program for hidradenitis suppurativa (HS).
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced a positive outcome of its final pre-BLA meeting held on April 1, 2026, with the FDA on the HS program of its Nanobody® SLK.
CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr.
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the firm's stock in a transaction on Friday, April 10th. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the completion of the transaction, the chief executive officer directly owned 2,976,766
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid-day trading on Friday. The company traded as low as $18.36 and last traded at $18.2540. 326,345 shares were traded during trading, a decline of 83% from the average session volume of 1,947,956 shares. The stock had previously closed at $19.41.
BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares.
ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology (AAD) Annual Meeting later today.
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) gapped up prior to trading on Thursday after Rothschild and Co Redburn upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $16.23, but opened at $17.20. Rothschild and Co Redburn now has a $40.00 price target on the stock, up
Cormorant Asset Management increased its MoonLake Immunotherapeutics position by 2,361,260 shares in the fourth quarter; the estimated trade value is $27.86 million based on average quarterly prices. The quarter-end value of the stake rose by $43.11 million, a figure reflecting both trading activity and stock price movement.
Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) by 51.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the company's stock after selling 2,150,000 shares during the period. MoonLake
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the sixteen analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
